What Is Selank?
Selank is a synthetic heptapeptide developed in Russia by the Institute of Molecular Genetics of the Russian Academy of Sciences. It was designed as a stable analogue of tuftsin, a naturally occurring tetrapeptide produced by the spleen that plays a role in immune regulation. By extending the tuftsin sequence and modifying its structure, researchers created a compound with significantly greater metabolic stability and a distinct psychopharmacological profile.
Unlike tuftsin, which breaks down rapidly in the bloodstream, Selank was engineered to cross the blood-brain barrier and exert effects on the central nervous system. It is administered either intranasally — via nasal drops, which allows direct absorption into the brain via the olfactory pathway — or subcutaneously by injection. The nasal route is the more commonly studied administration method in the available literature.
Selank has been approved in Russia as an anxiolytic and nootropic agent under the trade name Selank, and it has been in clinical use there since the mid-2000s. Outside of Russia, it remains a research compound with no approved therapeutic status in the EU, UK, or United States.
How It Works — The Mechanism
Selank appears to work through several overlapping pathways, which may explain why its profile differs from conventional anxiety medications.
The most studied mechanism involves modulation of the GABAergic system — the brain's primary inhibitory signalling network. GABA (gamma-aminobutyric acid) is the neurotransmitter that reduces neuronal excitability, producing calming effects. Classic anxiolytic drugs such as benzodiazepines work by amplifying GABA signalling at the GABA-A receptor. Selank appears to influence GABAergic tone, but through a modulatory rather than direct agonist mechanism. This distinction is considered significant in the research literature because direct GABA-A agonism is associated with tolerance, physical dependence, and withdrawal — effects that have not been observed with Selank in the published studies to date.
Beyond GABAergic effects, Selank has been shown in animal and in vitro studies to increase the expression of brain-derived neurotrophic factor (BDNF), a protein that supports the growth, survival, and differentiation of neurons. BDNF is strongly associated with learning, memory consolidation, and stress resilience. Low BDNF levels are observed in conditions including depression and chronic stress disorders. The upregulation of BDNF by Selank is one of the proposed explanations for its reported cognitive effects.
Selank also appears to influence serotonin metabolism, increasing the activity of serotonin-degrading enzymes and modulating serotonin availability in ways that may contribute to mood stabilisation. There is also evidence of interaction with the opioid and dopamine systems, though these pathways are less thoroughly characterised.
Finally, given its origins as a tuftsin analogue, Selank retains some immunomodulatory properties, with research indicating effects on interleukin expression and immune cell activity — though the relevance of this to its anxiety-reducing profile in humans remains unclear.
What Does the Research Say?
The body of research on Selank is real but limited in scope and predominantly Russian-language, which creates a significant access and verification challenge for researchers outside Russia.
The most cited human clinical evidence comes from Russian trials conducted in the late 1990s and 2000s, involving patients with generalised anxiety disorder (GAD). One series of studies reported that intranasal Selank at doses of approximately 400 micrograms per day produced anxiolytic effects comparable to medazepam (a benzodiazepine) over a treatment period of 10–14 days, without the sedation, cognitive blunting, or dependency risk associated with benzodiazepines. Participants in these trials reportedly showed improvements on standardised anxiety rating scales. However, many of these studies were conducted in relatively small cohorts, and the trial methodology has not been independently replicated in peer-reviewed Western clinical settings.
In animal models, the evidence is broader. Rodent studies have demonstrated dose-dependent reductions in anxiety behaviour on elevated plus-maze and open-field tests. BDNF upregulation has been documented in rat brain tissue following Selank administration. Cognitive performance under stress conditions — tasks requiring sustained attention and working memory — has also been shown to improve in animal studies. Importantly, these studies consistently note an absence of sedation at anxiolytic doses, which distinguishes Selank from most classical anxiolytics in animal testing.
Research into Selank's nootropic properties, meaning its potential to enhance cognitive function beyond simply reducing anxiety, is a smaller but growing area. Some studies suggest improved learning and memory consolidation in animal models, with BDNF induction proposed as a likely mediator. A 2014 study published in the journal Molecular Biology examined gene expression changes following Selank administration and found modulation of several genes involved in synaptic plasticity and neuroprotection.
The honest summary for researchers is this: the compound has a plausible mechanism, consistent animal data, and early-stage human evidence supporting its anxiolytic profile — but the clinical evidence base is shallow by Western pharmaceutical standards, with limited independent replication, small sample sizes, and a concentration of primary research in one country's scientific infrastructure. The English-language literature remains sparse, and peer review of the Russian clinical trials by international bodies has not been systematic.
Context for Irish Researchers
In Ireland, Selank has no approved therapeutic status and is not licensed by the Health Products Regulatory Authority (HPRA) as a medicinal product for human use. The HPRA is responsible for regulating medicines, medical devices, and related products in Ireland, and any substance intended for therapeutic use in humans must meet the full requirements of the EU medicinal products framework before it can be lawfully marketed or prescribed.
Selank is not a controlled substance under Irish or EU law as of mid-2026, which means its legal status as a research chemical places it in a grey area rather than an explicitly prohibited category. However, sourcing, importing, or supplying it with claims related to human therapeutic use would bring it within the scope of HPRA jurisdiction and medicines legislation. Researchers and academics interested in Selank should be clear-eyed about this distinction and ensure any work involving the compound is conducted within appropriate institutional frameworks.
For Irish health researchers, sports scientists, or neuroscience professionals with an interest in peptide pharmacology, Selank represents an interesting example of a compound that has completed a full regulatory pathway in one jurisdiction (Russia) while remaining a research-only substance elsewhere. This gap between formal approval and international evidence validation is common in the peptide research space and is worth understanding as a category-level consideration, not just as it applies to Selank specifically.
The Irish market for research peptides is growing, and with that growth comes a responsibility to engage with the evidence base seriously rather than selectively. Selank's profile — real mechanism, real animal data, limited human evidence, no known serious adverse events in the published literature — makes it a compound where the research conversation is worth having, provided it remains a research conversation.
Key Takeaways
- Selank is a synthetic analogue of the immune peptide tuftsin, developed in Russia and approved there as an anxiolytic and nootropic agent.
- It is administered intranasally or subcutaneously, with intranasal being the primary route studied in clinical contexts.
- Its proposed mechanisms include GABAergic modulation, BDNF upregulation, and serotonin system interaction — without the direct GABA-A agonism associated with benzodiazepine dependency.
- Russian clinical trials suggest anxiolytic effects comparable to benzodiazepines, without sedation or dependency, but independent replication in Western clinical trials is limited.
- Animal data is more robust — consistent reductions in anxiety behaviour, cognitive protection under stress, and BDNF increases have been documented across multiple rodent studies.
- The English-language evidence base is sparse, and researchers should weigh this alongside the positive signals in the available literature.
- In Ireland, Selank has no HPRA approval and should be treated as a research compound only, with sourcing and use governed by appropriate institutional and legal frameworks.
- For those tracking developments in peptide research, Selank's mechanism and early clinical profile make it a compound worth following as the evidence base matures.
For research tools, protocol guides, and supporting resources relevant to peptide research in Ireland, visit irishpeptides.ie/free-tools.